Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

Generalized pustular psoriasis, or GPP, is a rare and severe form of the autoimmune disease psoriasis.A GPP flare involves a widespread rash accompanied by pustules — small bumps containing pus ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Mark G. Lebwohl, MD, gives an overview of generalized pustular psoriasis (GPP) and explains how it differs from the more common plaque psoriasis.

Generalized pustular psoriasis or von Zumbusch psoriasis. Red, painful, tender skin blotches show up over a wide area of your body, and pus-filled blisters pop up soon after.

Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening autoinflammatory skin disease characterized by widespread eruption of sterile, visible pustules that occurs with or ...

An international consensus statement on generalized pustular psoriasis (GPP) from the International Psoriasis Council (IPC) includes the recommendation that considerations such as body surface ...

But we know with generalized pustular psoriasis [GPP], IL-36 plays a unique role. Talk to us a little bit about what’s different in IL-36 and why is it uniquely positioned for GPP patients.